ReviewBreathe (Sheffield, England)2024
Lung cancer screening: where do we stand?
Review in Breathe (Sheffield, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cost-Effectiveness and Budget Impact of Lung Cancer Screening: A Systematic Review.PharmacoEconomics · 2026Pooled it
- Prediction models for early detection and diagnosis of lung cancer in people who have never smoked: a systematic review and critical appraisal.Cancer causes & control : CCC · 2026Pooled it
- Article
- Education and training in low-dose CT lung cancer screening across Europe: a survey study.Insights into imaging · 2026Article
- Molecular cancer prevention: Intercepting disease.Molecular oncology · 2026Review
- Use of Tobacco and Alternative Nicotine Products Among People with HIV: A Cross-Sectional Multicenter Survey.AIDS and behavior · 2026Article
- Towards Personalised Screening for Lung Cancer: A Sex-Stratified Approach in a Danish Cohort Integrating Pre-Diagnostic Systemic Inflammatory Indexes with Smoking Status and Age.Respiration; international review of thoracic diseases · 2026Article
- Article
- ERS Congress 2025: highlights from the Thoracic Oncology Assembly.ERJ open research · 2026Article
- Engaging Culturally and Linguistically Diverse Communities to Prepare for Lung Cancer Screening Implementation in Australia: A Qualitative Focus Group Study.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Incidence of Second Primaries and Recurrent Disease in Early-Stage Lung Cancer: What Can We Expect in a Nodule-Care Center Cohort?Respiration; international review of thoracic diseases · 2026Article
- Review
- Advances and challenges in circulating tumor DNA-based early detection of lung cancer.Translational cancer research · 2025Review
- Nodule Characteristics, Clinical Risk Factors, and Radiologist Experience as Predictors of Positive Baseline LDCT Screening Results.Healthcare (Basel, Switzerland) · 2025Article
- Structured narrative review on lung cancer screening: current evidence, clinical practice implications and implementation insights from a multidisciplinary task force and patient representatives.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Src and Abl as Therapeutic Targets in Lung Cancer: Opportunities for Drug Repurposing.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Updates on lung cancer screening for early detection.The Korean journal of internal medicine · 2025Review
- Precision Medicine in Lung Cancer Screening: A Paradigm Shift in Early Detection-Precision Screening for Lung Cancer.Diagnostics (Basel, Switzerland) · 2025Review
- Development of a Pulmonary Nodule Service and Clinical Pathway: A Pragmatic Approach Addressing an Unmet Need.Diagnostics (Basel, Switzerland) · 2025Article
- ERS Congress 2024: highlights from the Thoracic Oncology Assembly.ERJ open research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer screening (LCS) programmes have emerged over recent years around the world. LCS programmes present differences in delivery, inclusion criteria and resource allocation. On a national scale, only a few LCS programmes have been fully established, but more are anticipated to follow. Evidence has shown that, in combination with a low-dose chest computed tomography scan, smoking cessation should be offered as part of a LCS programme for improved patient outcomes. Promising tools in LCS include further refined risk prediction models, the use of biomarkers, artificial intelligence and radiomics. However, these tools require further study and clinical validation is required prior to routine implementation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.